Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs)
Sponsor: The University of Hong Kong
Listed as NCT03071822, this PHASE4 trial focuses on Peripheral T Cell Lymphoma and remains ongoing. Sponsored by The University of Hong Kong, it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Apr 2022 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE4
-
Jul 2018 — Jan 2021 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE4
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The University of Hong Kong
For direct contact, visit the study record on ClinicalTrials.gov .